Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1981 Feb;43(2):260–269.

Complement-inhibiting and anti-inflammatory properties of chlorazole fast pink 2BL.

N S Doherty
PMCID: PMC1537288  PMID: 7273480

Abstract

Chlorazole fast pink 2BL inhibited the classical complement pathway in rat serum both in vivo and in vitro. The in vitro potency of chlorazole fast pink against the alternative pathway could not be assessed accurately but it was clearly less than that against the classical pathway. The compound appears to bind strongly to albumin with a resulting decrease in potency in undiluted as compared to diluted serum. Anti-inflammatory activity was observed in models of inflammation known to be highly complement-dependent (direct passive Arthus, zymosan oedema) but not in models in which complement is not involved (dextran oedema) or plays a minor role (carrageenan oedema).

Full text

PDF
260

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BORSOS T., RAPP H. J., CRISLER C. THE INTERACTION BETWEEN CARRAGEENAN AND THE FIRST COMPONENT OF COMPLEMENT. J Immunol. 1965 May;94:662–666. [PubMed] [Google Scholar]
  2. Brockman J. A., Bauman N. A capillary diffusion method for determining hemolytic complement activity in undiluted serum . J Immunol Methods. 1979;27(4):353–361. doi: 10.1016/0022-1759(79)90212-6. [DOI] [PubMed] [Google Scholar]
  3. Conrow R. B., Bauman N., Brockman J. A., Bernstein S. Synthetic modulators of the complement system. 1. Synthesis and biological activity of 5,5',5''-[1,3,6-naphthalenetriyltris(sulfonylimino)]-tris[1,3-benzenedisulfonic acid] hexasodium salt. J Med Chem. 1980 Mar;23(3):240–242. doi: 10.1021/jm00177a006. [DOI] [PubMed] [Google Scholar]
  4. DAVIES G. E. INHIBITION OF COMPLEMENT BY CARRAGEENIN: MODE OF ACTION, EFFECT ON ALLERGIC REACTIONS AND ON COMPLEMENT OF VARIOUS SPECIES. Immunology. 1965 Mar;8:291–299. [PMC free article] [PubMed] [Google Scholar]
  5. DAVIES G. E. INHIBITION OF GUINEA-PIG COMPLEMENT IN VITRO AND IN VIVO BY CARRAGEENIN. Immunology. 1963 Nov;6:561–568. [PMC free article] [PubMed] [Google Scholar]
  6. Di Rosa M. Biological properties of carrageenan. J Pharm Pharmacol. 1972 Feb;24(2):89–102. doi: 10.1111/j.2042-7158.1972.tb08940.x. [DOI] [PubMed] [Google Scholar]
  7. Doherty N. S., Robinson B. V. Some biological and pharmacological properties of inflammatory exudates. J Pharm Pharmacol. 1976 Dec;28(12):859–864. doi: 10.1111/j.2042-7158.1976.tb04080.x. [DOI] [PubMed] [Google Scholar]
  8. Glovsky M. M., Ward P. A., Becker E. L., Halbrook N. J. Role of fumaropimaric acid in guinea pig complement dependent and non-complement dependent biologic reactions. I. Inhibition of Forssman, reversed passive arthus, and PCA reactions by fumaropimaric acid. J Immunol. 1969 Jan;102(1):1–14. [PubMed] [Google Scholar]
  9. Götze O., Müller-Eberhard H. J. The C3-activator system: an alternate pathway of complement activation. J Exp Med. 1971 Sep 1;134(3 Pt 2):90s–108s. [PubMed] [Google Scholar]
  10. Hanahoe T. H., Holliman A., Gordan D., Wieczorek W. Disodium cromoglycate and the dextran response in rats. J Pharm Pharmacol. 1972 Aug;24(8):666–667. doi: 10.1111/j.2042-7158.1972.tb09085.x. [DOI] [PubMed] [Google Scholar]
  11. Johnson B. J. Complement: a host defense mechanism ready for pharmacological manipulation? J Pharm Sci. 1977 Oct;66(10):1367–1377. doi: 10.1002/jps.2600661005. [DOI] [PubMed] [Google Scholar]
  12. Jones B. M. The quantitation of alternative pathway complement function by timed lysis assay. J Immunol Methods. 1979;29(3):287–292. doi: 10.1016/0022-1759(79)90317-x. [DOI] [PubMed] [Google Scholar]
  13. LAMBERT H. P., RICHLEY J. The action of mucin in promoting infections: the anticomplementary effect of mucin extracts and certain other substances. Br J Exp Pathol. 1952 Aug;33(4):327–339. [PMC free article] [PubMed] [Google Scholar]
  14. PARRATT J. R., WEST G. B. 5-Hydroxytryptamine and the anaphylactoid reaction in the rat. J Physiol. 1957 Nov 14;139(1):27–41. doi: 10.1113/jphysiol.1957.sp005872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Saeki K. Anti-inflammatory properties of sulfated polysaccharides and activation of the plasma kinin-forming systems. Arch Int Pharmacodyn Ther. 1972 Jan;195(1):33–51. [PubMed] [Google Scholar]
  16. Thompson R. A., Lachmann P. J. Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med. 1970 Apr 1;131(4):629–641. doi: 10.1084/jem.131.4.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. WARD P. A., COCHRANE C. G. BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. J Exp Med. 1965 Feb 1;121:215–234. doi: 10.1084/jem.121.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Willoughby D. A., Coote E., Turk J. L. Complement in acute inflammation. J Pathol. 1969 Feb;97(2):295–305. doi: 10.1002/path.1710970215. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES